Gene disruption of tissue transglutaminase

Mol Cell Biol. 2001 Jan;21(1):148-55. doi: 10.1128/MCB.21.1.148-155.2001.

Abstract

Transglutaminase 2 (TGase 2), or tissue transglutaminase, catalyzes either epsilon-(gamma-glutamyl)lysine or N(1), N(8)-(gamma-glutamyl)spermidine isopeptide bonds. TGase 2 expression has been associated with apoptosis, and it has been proposed that its activation should lead to the irreversible assembly of a cross-linked protein scaffold in dead cells. Thus, TGase 2-catalyzed protein polymerization contributes to the ultrastructural changes typical of dying apoptotic cells; it stabilizes the integrity of the apoptotic cells, preventing the release of harmful intracellular components into the extracellular space and, consequently, inflammation and scar formation. In order to perform a targeted disruption of the enzyme, we prepared a construct deleting part of exons 5 and 6, containing the active site, and intron 5. Complete absence of TGase 2 was demonstrated by reverse transcription-PCR and Western blot analysis. TGase activity measured on liver and thymus extracts showed, however, a minimal residual activity in TGase 2(-/-) mice. PCR analysis of mRNA extracted from the same tissues demonstrated that at least TGase 1 (normally present in the skin) is also expressed in these tissues and contributes to this residual activity. TGase 2(-/-) mice showed no major developmental abnormalities, and histological examination of the major organs appeared normal. Induction of apoptosis ex vivo in TGase 2(-/-) thymocytes (by CD95, dexamethasone, etoposide, and H(2)O(2)) and in vitro on TGase 2(-/-) mouse embryonal fibroblasts (by retinoids, UV, and H(2)O(2)) showed no significant differences. A reduction in cross-linked apoptotic bodies with a modestly increased release of lactate dehydrogenase has been detected in some cases. Together our results show that TGase 2 is not a crucial component of the main pathway of the apoptotic program. It is possible that the residual enzymatic activity, due to TGase 1 or redundancy of other still-unidentified TGases, can compensate for the lack of TGase 2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis* / drug effects
  • Apoptosis* / radiation effects
  • Cells, Cultured
  • Dexamethasone / pharmacology
  • Etoposide / pharmacology
  • GTP-Binding Proteins / deficiency*
  • GTP-Binding Proteins / genetics
  • GTP-Binding Proteins / metabolism*
  • Gene Deletion*
  • Gene Targeting
  • Hydrogen Peroxide / pharmacology
  • Isoenzymes / deficiency
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • Leukocyte Common Antigens / physiology
  • Liver / enzymology
  • Mice
  • Mice, Knockout
  • Mutagenesis, Insertional / genetics*
  • Ploidies
  • Protein Glutamine gamma Glutamyltransferase 2
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Recombination, Genetic
  • Skin / enzymology
  • Thymus Gland / cytology
  • Thymus Gland / drug effects
  • Thymus Gland / enzymology
  • Transglutaminases / deficiency*
  • Transglutaminases / genetics
  • Transglutaminases / metabolism*
  • Tretinoin / pharmacology
  • Ultraviolet Rays

Substances

  • Isoenzymes
  • RNA, Messenger
  • Tretinoin
  • Etoposide
  • Dexamethasone
  • Hydrogen Peroxide
  • Protein Glutamine gamma Glutamyltransferase 2
  • Transglutaminases
  • Leukocyte Common Antigens
  • GTP-Binding Proteins

Grants and funding